Previous 10 | Next 10 |
TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today multiple presentations regarding CGuard EPS, includin...
Nasdaq & NYSE Penny Stocks To Watch This Week We always talk about following trends when it comes to penny stocks . It might be a niche like electric vehicles or an entire sector like biotech. On this note, the latter has been one of the hottest corners of the stock market today...
Are These Robinhood Penny Stocks On Your “Buy” or “Avoid” List This Week? One question traders continue asking themselves is this: “ Are penny stocks worth it? ” It’s not an uncommon question to ask considering the current state o...
InspireMD, Inc. (NSPR) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants Scott Gordon - President, Core IR, Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjamin Haynor - Alliance...
InspireMD (NSPR): Q3 GAAP EPS of -$0.06 beats by $0.02.Revenue of $0.98M (+4.3% Y/Y) beats by $0.58M.Press Release For further details see: InspireMD EPS beats by $0.02, beats on revenue
Third quarter 2020 revenue returns to pre-COVID-19 levels Management to host investor conference call today, November 9, 2020 at 8:30 a.m. ET TEL AVIV, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR)(“Inspire” or the ȁ...
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of An...
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of An...
TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), toda...
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Gary Roubin, M.D., Ph.D., to In...
News, Short Squeeze, Breakout and More Instantly...
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prev...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...